According to a recent LinkedIn post from Corvia Medical Inc, the company is highlighted at the THT2026 meeting in Boston with presentations on its Corvia Atrial Shunt. The post points to 5-year outcomes from the REDUCE LAP-HF II study, which it describes as the longest follow-up available in atrial shunt therapy for heart failure patients.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post also notes additional conference sessions focused on interatrial shunting in heart failure, including long-term outcomes and clinical considerations. For investors, the visibility of long-term clinical data and expert discussion may be relevant to assessing the technology’s clinical validation, potential adoption in HFpEF treatment, and Corvia Medical’s positioning in the structural heart device segment.